Fairvalue-Calculator Fairvalue-Calculator
EN DE

Yuyu Pharma, Inc (000227) Fair Value & Analysis

Healthcare · KR · Market cap 39.4B KRW

Price10,280 KRW
Fair Value30,609 KRW
Upside+197.8%
Quality87/100
Evidence: Medium Range 22,617 KRW – 38,268 KRW

Fair value as of: Jun 25, 2026

Analysis

Yuyu Pharma, Inc (000227) currently trades at 10,280 KRW, while our model-based Fair Value estimate is 30,609 KRW — implying the stock looks roughly 197.8% undervalued today. We read business quality at 87/100 (high quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: medium) — always confirm before acting.

About the company

Yuyu Pharma, Inc. develops and markets pharmaceutical products in Korea and United States. The company offers various prescription drugs, non-prescription drugs, quasi-drugs, health functional foods, and other products in the fields of neurology, endocrinology, otolaryngology, etc. The company was formerly known as YuYu Inc. and changed its name to Yuyu Pharma, Inc. in May 2008. Yuyu Pharma, Inc. was founded in 1941 and is headquartered in Jecheon-si, South Korea.

Open the full interactive analysis →

Similar stocks

Takeda Pharmaceutical Company (TAKP34) +3193% Jiangsu Hengrui Pharmaceuticals Co (600276) -37% Sun Pharmaceutical Industries Limited (SUNPHARMA) -44% Zoetis Inc (Z1TS34) -1% Hansoh Pharmaceutical Group (3692) -37% Divi's Laboratories Limited (DIVISLAB) -70%

Frequently asked questions

Is Yuyu Pharma, Inc (000227) undervalued?
As of Jun 25, 2026, our model estimates a fair value of 30,609 KRW versus a price of 10,280 KRW — about +198% (undervalued). Model-based estimate, not financial advice.
What is the fair value of 000227?
Our 21-model fair value for Yuyu Pharma, Inc is 30,609 KRW (as of Jun 25, 2026), built from audited fundamentals. The current price is 10,280 KRW.
What is the quality score of 000227?
Yuyu Pharma, Inc has a Quality Score of 87/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.